HISUN

海正动保

HISUN Veterinary Biotech Co., Ltd. is a holding subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. It has the following brand advantages:

Strong enterprise strength: Inheriting the craftsmanship spirit and quality of Hisun Pharmaceuticals, it has invested 800 million yuan to build an international animal health enterprise.

Perfect production bases: It has two major production bases, namely Fuyang Chemical Drugs and Kunming Vaccines. It has passed the GMP certification of the Ministry of Agriculture of China and the APVMA certification of the Australian Ministry of Agriculture. It has multiple production lines for multiple dosage forms, achieving comprehensive development in serialization and specialization.

Comprehensive product layout: It covers four major fields: pig business, ruminant business, pet business, and vaccine business, with more than 40 existing products. In terms of the pet business, it is the leading brand of pet drugs in China. Its R&D pipeline ranks among the top among Chinese enterprises. In the next three years, more than ten products in the fields of pet drugs and vaccines will be successively launched. For example, in terms of anthelmintic drugs, there are several pioneering products. Such as the first avermectin anthelmintic drug launched in China in 1993, it became the first company to launch the product of monensin in China in 2000, the first doramectin API in China in 2008, obtained the approval for milbemycin oxime API in 2010, the approval for the second-class new veterinary drug of milbemycin oxime tablets for dogs (Helechong) in 2014, the approval for the compound tablets of milbemycin oxime + praziquantel for cats (Helemiao) in 2015, and the first Chinese legal and compliant internal and external ectoparasite repellent, imidacloprid + moxidectin drops (Moaijia), was approved for listing in August 2021, etc.

Strong R&D capabilities: As of September 2021, it has 7 invention patents for preparations, 24 utility model patents, and 4 design patents; it has accumulated a total of 26 new drug preparation certificates (9 of category 2, 7 of category 3, 2 of category 4, and 8 of category 5); among the 202 completed research and development and registrations of new chemical veterinary drugs across China from 2010 to 2020, Hisun occupied 21 seats, accounting for 10%.

Product quality guarantee: It has reached the quality system of human drugs and the quality standards of imported drugs.

Enterprise mission and vision: Committed to R&D, manufacturing, sales and service, adhering to the sacred mission of “Good drugs with a sincere heart fulfill the dream of health”, with the slogan of “Innovation for the health of you and it”, and pursuing to become a “globalized and sustainable leading national pharmaceutical enterprise”.

Its mission is to provide complete and effective animal health solutions for farm animals and companion animals and care for animal health. In April 2024, the first heavyweight product “Yunyuanqing” (combined inactivated vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae) in the vaccine field of HISUN Veterinary Biotech Co., Ltd. was officially launched, marking the realization of the “chemical drugs + vaccines” dual-wheel drive development of HISUN Veterinary Biotech Co., Ltd., providing a closed-loop protection for the full life cycle of animal health.

Best-selling Products from the HISUN Brand：